Myocyte-specific enhancer factor 2A (MEF2A)

Myocyte-specific enhancer factor 2A (MEF2A) is a DNA-binding transcription factor belonging to the MADS box family, essential for the regulation of muscle gene expression and development, as well as neuronal differentiation and maintenance[1][4][5]. MEF2A binds as a dimer—sometimes forming heterodimers with related MEF2 proteins—to regulatory sequences present in many muscle-specific and stress-responsive genes. It is central to pathways governing skeletal and cardiac muscle development, programmed cell death, and cytoskeletal organization. In humans, mutations in MEF2A are linked to autosomal dominant coronary artery disease and myocardial infarction[1][5]. MEF2A's diverse roles are mediated through its dynamic interactions with other transcription factors (such as STAT3), co-factors, and chromatin modifiers (notably HDACs), making it a nodal point in cell survival and stress responses, particularly in the heart and muscle. While not a direct therapeutic target as of 2024, altered MEF2A activity or expression is relevant for diseases including cardiovascular disease, cancer, and neurological disorders[3][4][5].

Other names

Myocyte-specific enhancer factor 2AMEF2AMEF2RSRFC4RSRFC9Serum response factor-like protein 1ADCAD1MADS box transcription enhancer factor 2 polypeptide A

Transcriptional regulation: MEF2A functions by binding to specific DNA sequences, activating or repressing transcription of target genes important for muscle and neuron function. Protein-protein interaction modulation: Interacts dynamically with partners such as HDACs (histone deacetylases), STAT3, and others, influencing cell survival, apoptosis, and differentiation.